Revised SPC: Ruconest (conestat alfa) 2100 U powder for solution for injection

The indication has been extended to children aged 2 years and above and more specific advice added that all patients must be closely monitored and observed for any symptoms of hypersensitivity during and after administration. Dizziness has been added as ADR of uncommon frequency.

electronic Medicines compendium